Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants

Relebactam is a novel class A and C β-lactamase inhibitor that is being developed in combination with imipenem-cilastatin for the treatment of serious infections with Gram-negative bacteria. Here we report on two phase 1 randomized, double-blind, placebo-controlled pharmacokinetics, safety, and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhee, Elizabeth G., Rizk, Matthew L., Calder, Nicole, Nefliu, Marcela, Warrington, Steven J., Schwartz, Michael S., Mangin, Eric, Boundy, Keith, Bhagunde, Pratik, Colon-Gonzalez, Francheska, Jumes, Patricia, Liu, Yang, Butterton, Joan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125551/
https://www.ncbi.nlm.nih.gov/pubmed/29914955
http://dx.doi.org/10.1128/AAC.00280-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125551/
https://www.ncbi.nlm.nih.gov/pubmed/29914955
http://dx.doi.org/10.1128/AAC.00280-18

Ejemplares similares